Efficacy and Safety of Mycophenolate Mofetil as Part of Induction Therapy in Liver Transplantation

Pareja-Ciuró, Felipe; Díez-Canedo, J. Serrano; Gómez‐Bravo, Miguel Ángel; García-González, Inmaculada; Tamayo-López, María Jesús; Sousa-Martı́n, J.M.; Pascasio-Acevedo, Juan Manuel; Porras-López, M.; Gavilán-Carrasco, F.; Bernardos-Rodríguez, A.

doi:10.1016/j.transproceed.2005.10.058

Cited by 3 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pareja-Ciuró et al [25] evaluated the efficacy and safety of MMF for induction and maintenance therapy to prevent acute liver transplant rejection. The non-randomized retrospective analysis with a follow-up of at least 2 years reported approximately 66 patients, of whom 39 received MMF, CNIs (tacrolimus levels 5-15 ng/ml, cyclosporin A levels 150-300 ng/ml) and steroids, 11 patients received IL-2 receptor antibodies, MMF, low-dose CNIs (tacrolimus levels 5-10 ng/ml, cyclosporin A levels 100-200 ng/ml) and steroids, and 16 patients received IL-2 receptor antibodies, MMF and low-dose CNIs without steroids.…”

Section: Mycophenolate Mofetilmentioning

confidence: 99%

The use of induction agents in liver transplantation

Grotelueschen

Fischer

Rogiers

2006

Current Opinion in Organ Transplantation

View full text Add to dashboard Cite

Purpose of reviewDespite improvements in early graft survival, late graft loss through chronic rejection and morbidity and mortality as a result of long-term treatment with immunosuppressive medications is a major concern. New drugs have facilitated new treatment protocols with the delayed or reduced application of calcineurin inhibitors or steroid avoidance. This review focuses on recent data concerning the use of induction agents in liver transplantation. Recent findingsClinical studies using induction agents have demonstrated their safety and efficacy, and show promise for a beneficial outcome in liver transplant patients. IL-2 receptor antibodies allow a reduction of maintenance immunosuppression and reduce side effects, such as diabetes or renal impairment. Several studies using IL-2 receptor antibodies have also shown a lower incidence of acute rejection episodes in paediatric patients. Thymoglobulin has been used primarily in hepatitis C-positive patients, and studies have shown a positive effect on virus replication without significant recurrence of hepatitis C. Alemtuzumab has shown promising results regarding acute rejection episodes and renal function in a low-dose calcineurin inhibitor protocol. SummaryThe use of induction agents in liver transplantation is a promising strategy to reduce acute rejection episodes, maintenance immunosuppression, and prevent side effects without affecting patient and graft survival.

show abstract

Section: Mycophenolate Mofetilmentioning

confidence: 99%

The use of induction agents in liver transplantation

Grotelueschen

Fischer

Rogiers

2006

Current Opinion in Organ Transplantation

View full text Add to dashboard Cite

show abstract

“…Immunosuppressive agents, such as cyclosporine A (CsA), were often used and had certain effectiveness in the asthmatic patients with glucocorticoid resistance [7][8][9], but its potential beneficial effects are outweighed by its toxicity especially to the kidneys. Mycophenolate mofetil (MMF) is a new immunosuppressant which is successfully used in the treatment for the rejection reaction in the organ transplantation [10,11] and its effectiveness on the immune-mediated inflammatory diseases is being investigated [12][13][14]. MMF has a relatively high selectivity in blocking the DNA synthesis of T cells [15].…”

Section: Introductionmentioning

confidence: 99%

Mycophenolate mofetil and triptolide alleviating airway inflammation in asthmatic model mice partly by inhibiting bone marrow eosinophilopoiesis

Mao¹,

Chen²,

Yi³

et al. 2008

International Immunopharmacology

View full text Add to dashboard Cite

Current awareness: Pharmacoepidemiology and drug safety

2006

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 20 sections: 1 Books, Reviews & Symposia; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Teratogens/fetal exposure; 20 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.

show abstract

Efficacy and Safety of Mycophenolate Mofetil as Part of Induction Therapy in Liver Transplantation

Cited by 3 publications

References 7 publications

The use of induction agents in liver transplantation

The use of induction agents in liver transplantation

Mycophenolate mofetil and triptolide alleviating airway inflammation in asthmatic model mice partly by inhibiting bone marrow eosinophilopoiesis

Current awareness: Pharmacoepidemiology and drug safety

Contact Info

Product

Resources

About